LAINE KEYSER: Open Payments
NPI 1902262777 · CHERRY HILL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,524 in 70 payments from 12 companies in 2025. Trend: 2023 $452 · 2024 $1,236 · 2025 $1,524
Food & beverage: $1,524
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $422 |
| QOL Medical, LLC | 8 | $249 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $207 |
| Ardelyx, Inc. | 4 | $187 |
| Janssen Biotech, Inc. | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $84 |
| GENZYME CORPORATION | 3 | $72 |
| Lilly USA, LLC | 2 | $37 |
| Celltrion USA Inc. | 2 | $36 |
Products named: Sucraid, IBSRELA, DUPIXENT, XIFAXAN, CREON, RINVOQ, TREMFYA, ENTYVIO.
Industry payments across NJ — which companies pay providers there.
